Patent claims on synergistic application of cepharanthine, cabazitaxel and other taxane family members used in combination to treat primary, metastatic and chemotherapy-resistant prostate cancer Expands on Company’s ‘pipeline in a pill’ strategy with...
Establishing cGMP supply for IND-enabling and up to Phase 2 clinical studies for PD-001 oral formulation for esophageal cancer and mild to moderate COVID-19 Toronto, Ontario – January 26, 2022 – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the...
VANCOUVER, British Columbia, Jan. 26, 2022 – Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) is pleased to provide a corporate update with regard to its operations. Despite the continuing challenges created by...
Toronto, Ontario – January 24, 2022 – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (FSE: G111) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as...
Vantage pursues Drug Master Files with the FDA to support the quality and safety of its products Greeley, Colorado, Jan. 24, 2022 – Vantage Hemp Co. (“Vantage” or the “Company”), an industry-leading manufacturer of pharmaceutical-grade CBD products, today...
Toronto, Ontario – January 20, 2022 – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and...
